Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Shield Thera (STX) Share Price

Price 9.85p on 02-01-2026 at 19:35:09
Change 0.00p 0%
Buy 10.00p
Sell 9.70p
Last Trade: Buy 10,410.00 at 10.00p
Day's Volume: 979,728
Last Close: 9.85p
Open: 9.85p
ISIN: GB00BYV81293
Day's Range 9.85p - 10.00p
52wk Range: 2.20p - 12.35p
Market Capitalisation: £104.59m
VWAP: 9.854071p
Shares in Issue: 1.06b

Shield Thera (STX) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 10,410 10.00p Ordinary
16:13:10 - 02-Jan-26
Buy* 40,444 9.9003p Ordinary
16:07:36 - 02-Jan-26
Buy* 10,000 10.00p Ordinary
16:05:29 - 02-Jan-26
Unknown* 500,000 9.75p Ordinary
15:59:40 - 02-Jan-26
Buy* 1 10.00p Ordinary
15:58:45 - 02-Jan-26
Buy* 4,368 9.9003p Ordinary
15:44:54 - 02-Jan-26
Buy* 417 9.8925p Ordinary
15:43:25 - 02-Jan-26
Unknown* 1,158 9.85p Ordinary
15:13:33 - 02-Jan-26
Sell* 1,000 9.7015p Ordinary
14:58:50 - 02-Jan-26
Buy* 1,925 10.00p Ordinary
14:56:02 - 02-Jan-26
See more Shield Thera trades

Shield Thera (STX) Share Price History

Time period:
to
Date Open High Low Close Volume
2nd Jan 2026 (Fri) 9.85 10.00 9.85 9.85 979,728
1st Jan 2026 (Thu) 9.85 9.85 9.85 9.85 0
31st Dec 2025 (Wed) 10.00 10.00 9.85 9.85 323,493
30th Dec 2025 (Tue) 10.30 10.30 9.90 10.00 3,185,187
29th Dec 2025 (Mon) 10.75 11.10 10.30 10.30 2,191,206
26th Dec 2025 (Fri) 10.75 10.75 10.75 10.75 0
25th Dec 2025 (Thu) 10.75 10.75 10.75 10.75 0
24th Dec 2025 (Wed) 10.65 10.875 10.70 10.75 936,425
23rd Dec 2025 (Tue) 11.00 10.90 10.90 10.90 1,095,089
22nd Dec 2025 (Mon) 11.50 12.00 11.00 11.00 4,205,530
19th Dec 2025 (Fri) 11.75 11.75 11.25 11.25 1,215,868
18th Dec 2025 (Thu) 11.75 11.75 11.75 11.75 527,678
17th Dec 2025 (Wed) 11.20 12.00 11.20 11.75 2,635,827
16th Dec 2025 (Tue) 10.70 11.25 11.00 11.20 4,192,777
15th Dec 2025 (Mon) 10.25 10.70 10.15 10.70 915,771
12th Dec 2025 (Fri) 10.25 10.25 10.15 10.25 1,326,273
11th Dec 2025 (Thu) 10.25 10.45 10.25 10.25 1,468,480
10th Dec 2025 (Wed) 10.25 10.20 9.56 10.20 5,494,454
9th Dec 2025 (Tue) 10.25 10.25 10.25 10.25 1,306,459
8th Dec 2025 (Mon) 11.50 11.35 10.50 10.50 4,496,875
5th Dec 2025 (Fri) 11.20 11.50 10.95 11.50 1,300,693
See more Shield Thera price history

Shield Thera (STX) Regulatory News

Date Source Headline
2nd Jan 2026 11:06 am RNS Block listing 6 Monthly Return
2nd Jan 2026 7:00 am RNS Total Voting Rights
2nd Jan 2026 7:00 am RNS Total Voting Rights
22nd Dec 2025 7:00 am RNS FDA approves extension for ACCRUFeR®
22nd Dec 2025 7:00 am RNS FDA approves extension for ACCRUFeR®
18th Dec 2025 7:13 am RNS Block Listing Application
11th Dec 2025 7:00 am RNS-R Shield Wins Gold at Titan Branding Awards
3rd Dec 2025 7:04 am RNS Amends Senior Secured Debt Financing
14th Nov 2025 7:03 am RNS Initiation of a Phase II Clinical Trial in Japan
11th Nov 2025 7:00 am RNS ACCRUFeR Pediatric PK Results to be Presented
See more Shield Thera regulatory news

Shield Thera (STX) Share News

EARNINGS AND TRADING: Corel loss widens; Christie sells Vennersys

22nd Dec 2025 15:38

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

Shield Therapeutics upbeat as Accrufer trial initiated in Japan

14th Nov 2025 12:08

(Alliance News) - Shield Therapeutics PLC on Friday reported the commencement of a phase two Accrufer trial in Japan for the treatment of pulmonary arterial hypertension. Read More

IN BRIEF: Shield receives approval from South Korea for Accrufer

7th Nov 2025 17:03

(Alliance News) - Shield Therapeutics PLC - Newcastle, England-based commercial-stage pharmaceutical company - Announces that the Korean Ministry of Food and Drug Safety has granted regulatory approval for Accrufer in South Korea for the treatment of iron deficiency in adult subjects. The approval follows submission of a new drug application by Korea Pharma in 2024 after the successful completion of a pharmacokinetic study. Shield is eligible to receive payments upon the first sale, as well as performance-based sales milestones and royalties on net sales. Read More

TRADING UPDATES: Shoe Zone wary ahead of budget; Nexus sales jump 16%

23rd Oct 2025 15:35

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Shield Therapeutics reports positive results in paediatric trial

1st Oct 2025 13:31

(Alliance News) - Shield Therapeutics PLC on Wednesday noted positive efficacy and tolerance results from in its phase three ferric maltol Fortis trial. Read More

See more Shield Thera news
FTSE 100 Latest
Value9,951.14
Change19.76

Login to your account

Forgot Password?

Not Registered